This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

CellHealth Institute Launches With Support From Influential Investors

MONTCLAIR, N.J., March 27, 2013 /PRNewswire/ -- CellHealth™ Institute (CHI), a new biotechnology company that provides breakthrough products, services and lifestyle education in the emerging category of personalized cell health has launched with the backing of key investors. John Malone Ph.D., chairman of Liberty Media Corporation (NASDAQ: LMCA) has invested $2 million in CellHealth Institute.


CellHealth Institute offers fully integrated and individualized health programs, paired with scientific biomarker evaluations, medical-grade supplements and informed advice for its clients and social community on healthy lifestyle choices to improve cell health. CellHealth Institute also provides advanced adult stem cell services, and has its own cell technology IP portfolio.

"The development of adult stem cell research and technology and the exciting progress in the world of cell health and regenerative medicine are the things that motivated me to invest in CellHealth Institute," said John Malone. "We know unequivocally that damage to human cells is at the core of most disease. We have a duty to research, develop and deliver to the doors of people across the United States and worldwide the products and services that can increase and enrich their quality of life. I believe that CellHealth Institute and the work of its team will lead us into the new frontier of preventative care and I'm excited to be a part of the progress that is being made."

The support of investors, including Mr. Malone, will enable CellHealth Institute to grow its research and product development plans as well as its consumer-facing strategy. CellHealth Institute, which is led by cell health expert and Chief Medical Officer Dr. Vincent Giampapa, the world's first board-certified anti-aging physician, will also continue to collaborate with top-tier universities and publicly traded companies in its research of advanced adult stem cell treatments.

"It is extremely gratifying to have John Malone, someone well recognized as having extraordinary business acumen with continuing success in many industries, so committed to our movement and the things we're trying to achieve," said David Saloff, chief executive officer of CellHealth Institute. "The concept of cell health is a new one to most people, but we want to ensure that it becomes widely understood and fast. The presence of exceptional visionaries like John Malone can only help us achieve our outreach with excellence."

Mr. Malone is joined in support of CellHealth Institute by Ed Bosarge, founder and CEO of Capital Technologies Inc. Dr. Bosarge, through the Bosarge Family Office, has funded CellHealth Institute's latest clinical study into reprogramming aging adult stem cells at the University of Medicine and Dentistry New Jersey (UMDNJ).

For more information, visit

About CellHealth™ Institute

CellHealth Institute (CHI) is a biotechnology company focused on cellular health that integrates breakthrough products and services with holistic lifestyle education. CHI collaborates with top-tier research universities and publicly traded biotech companies to offer fully integrated personalized health programs paired with scientific biomarker evaluations, as well as medical-grade supplements, including EveryCell™, and advanced treatment through stem cell therapies. The organization is headquartered in New Jersey with an international regenerative medicine destination in Costa Rica set to open in 2014. CHI services and products allow people to take control of their own health at the most basic level – their cells.

SOURCE CellHealth Institute

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 16,749.20 -27.23 -0.16%
S&P 500 1,975.78 -11.27 -0.57%
NASDAQ 4,725.1930 -56.0710 -1.17%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs